Pay in 4 interest-free payments of $5.36 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
Retatrutide is an investigational triple agonist peptide (GIP, GLP-1, and glucagon receptor) currently under clinical development for the management of obesity and type 2 diabetes
In a recent regulatory shift, the FDA has ended the allowance for compounding pharmacies to produce copycat versions of popular GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound)
Consult a licensed healthcare provider before starting, stopping, or changing any medication
Patients should not inject research-use or online products marketed as retatrutide
US$ 27.41
US$ 24.45
US$ 24.44
